Company / Net Income
MADRIGAL PHARMACEUTICALS, INC. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$288.3M
FY2025
5-year range
-$465.9M / -$241.8M
FY2021-FY2025
Trend
+38.1%
vs FY2024
Sector context
#176 of 216
Health Care
What the data says
MADRIGAL PHARMACEUTICALS, INC.'s net income of -$288M is lower than 81% of companies in the Health Care sector (FY2025). Net Income returned to growth in FY2025 after 8 years of decline, reaching -$288M.
Based on SEC 10-K filings.
-$288M in FY2025.
Improved from -$374M to -$288M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 216This company -$288.3M Sector average $454.3M
▼
-163.5% below sector average
Key checks
Key Insights
- In FY2025, net income increased 38.1% year-over-year.
- Ranks #176 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$288.3M | +38.1% |
| FY2024 | -$465.9M | -24.7% |
| FY2023 | -$373.6M | -26.5% |
| FY2022 | -$295.4M | -22.1% |
| FY2021 | -$241.8M | -19.6% |
| FY2020 | -$202.2M | -140.9% |
| FY2019 | -$83.9M | -155.9% |
| FY2018 | -$32.8M | -5.3% |
| FY2017 | -$31.2M | -18.1% |
| FY2016 | -$26.4M | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026